Evidence map›Paper›PMID 28936620›Full record

ArticleMammalian genome : official journal of the International Mammalian Genome Society2017

Osteoclast stimulation factor 1 (Ostf1) KNOCKOUT increases trabecular bone mass in mice.

Matthieu Vermeren, Rodanthi Lyraki, Sachin Wani, Rannar Airik, Omar Albagha, Richard Mort, Friedhelm Hildebrandt, Toby Hurd

Open access · hybridAbstract read
In one paragraph

Article in Mammalian genome : official journal of the International Mammalian Genome Society, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 26 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Network-based Transcriptome-wide Expression Study for Postmenopausal Osteoporosis.The Journal of clinical endocrinology and metabolism · 2020
    Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Matthieu VermerenInstitute for Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital Campus, Crewe Road, Edinburgh, EH4 2XU, UK.
Rodanthi LyrakiInstitute for Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital Campus, Crewe Road, Edinburgh, EH4 2XU, UK.
Sachin WaniInstitute for Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital Campus, Crewe Road, Edinburgh, EH4 2XU, UK.
Rannar AirikRangos Research Center, Children's Hospital of Pittsburgh, Pittsburgh, PA, 15224, USA.
Omar AlbaghaInstitute for Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital Campus, Crewe Road, Edinburgh, EH4 2XU, UK.
Richard MortDivision of Biomedical and Life Sciences, Faculty of Health and Medicine, Lancaster University, Lancaster, LA1 4YG, UK.
Friedhelm HildebrandtDivision of Nephrology, Boston Children's Hospital, Harvard Medical School, Enders 561, 300 Longwood Avenue, Boston, MA, 02115, USA.
Toby HurdInstitute for Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital Campus, Crewe Road, Edinburgh, EH4 2XU, UK. Toby.Hurd@Igmm.ed.ac.uk.ORCID 0000-0003-1533-1171
Western General Hospital · GBBoston Children's Hospital · USChildren's Hospital of Pittsburgh · USLancaster University · GB

Funding

The role of DNA damage response signaling in chronic kidney diseaseR00DK099434 · NIDDK · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI AIRIK, RANNAR · 2015 to 2017
$733k
College of Medicine and Veterinary Medicine, University of Edinburgh Chancellor's FellowshipNIDDK NIH HHS R00 DK099434
6 · The paper itself

Abstract

Osteoclast stimulation factor 1 (OSTF1) is an SH3-domain containing protein that was initially identified as a factor involved in the indirect activation of osteoclasts. It has been linked to spinal muscular atrophy in humans through its interaction with SMN1, and is one of six genes deleted in a human developmental microdeletion syndrome. To investigate the function of OSTF1, we generated an Ostf1 knockout mouse model, with exons 3 and 4 of Ostf1 replaced by a LacZ orf. Extensive X-Gal staining was performed to examine the developmental and adult expression pattern, followed by phenotyping. We show widespread expression of the gene in the vasculature of most organs and in a number of cell types in adult and embryonic mouse tissues. Furthermore, whilst SHIRPA testing revealed no behavioural defects, we demonstrate increased trabecular mass in the long bones, confirming a role for OSTF1 in bone development.

Indexed as

AnimalsBone and BonesBone DensityCells, CulturedExonsHEK293 CellsHumansIntracellular Signaling Peptides and ProteinsMiceMice, Inbred C57BLMice, KnockoutOsteoclastsPeptidesIntracellular Signaling Peptides and Proteinsosteoclast stimulating factorPeptides

Identifiers

PMID28936620
PMCPMC5680368
OpenAlexW2757001097

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.